Drug intelligence / Profile preview

bromocriptine + octreotide

Development stage: Unknown
Lead developer: Novartis
Modality: Peptides, Small Molecules
Administration: Oral, Subcutaneous, Intramuscular

Overview

A combination therapy consisting of bromocriptine, a dopamine D2 receptor agonist, and octreotide, a somatostatin analog. This combination is primarily used for treating acromegaly and has been shown to reduce growth hormone (GH) and insulin-like growth factor-I (IGF-I) levels more effectively than either drug alone. The bioavailability of bromocriptine increases by approximately 40% when administered together with octreotide.

Targets

SSTR2 (Somatostatin receptor type 2)DRD2 (Dopamine D2 Receptor)SSTR5 (Somatostatin receptor 5)

Beyond the preview

Go deeper on bromocriptine + octreotide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bromocriptine + octreotide.

Explore the full profile